-+ 0.00%
-+ 0.00%
-+ 0.00%

TheraCryf Files Ethics Application for First-Stage Study of Orexin-1 Addiction Program

MT Newswires·11/18/2026 04:15:12
语音播报
04:15 AM EST, 11/18/2026 (MT Newswires) -- TheraCryf (TCF.L) submitted an ethics application in Australia for a first-in-human phase 1 clinical trial of its lead orexin-1 receptor antagonist, which is being developed to treat addiction. The application was filed with the Bellberry Human Research Ethics Committee through its Australian subsidiary, following completion of the required preclinical data package, according to a Wednesday release. Subject to ethics committee approval, the clinical-stage therapeutics company will file a clinical trial notification with Australia's Therapeutic Goods Administration. It continues to target the necessary approvals by the end of 2026.